Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

被引：30

作者：

El Zarif, Talal ^{[1
]}

Nassar, Amin H. ^{[2
]}

Adib, Elio ^{[1
,3
]}

Fitzgerald, Bailey G. ^{[4
]}

Huang, Jiaming ^{[1
]}

Mouhieddine, Tarek H. ^{[4
]}

Rubinstein, Paul G. ^{[5
]}

Nonato, Taylor ^{[6
]}

McKay, Rana R. ^{[6
]}

Li, Mingjia ^{[7
]}

Mittra, Arjun ^{[7
]}

Owen, Dwight H. ^{[7
]}

Baiocchi, Robert A. ^{[8
]}

Lorentsen, Michael ^{[9
]}

Dittus, Christopher ^{[9
]}

Dizman, Nazli

Falohun, Adewunmi ^{[10
]}

Abdel-Wahab, Noha ^{[10
,11
]}

Diab, Adi ^{[10
]}

Bankapur, Anand ^{[12
]}

Reed, Alexandra ^{[12
]}

Kim, Chul ^{[13
]}

Arora, Aakriti ^{[14
]}

Shah, Neil J. ^{[15
]}

El-Am, Edward ^{[16
]}

Kozaily, Elie ^{[16
]}

Abdallah, Wassim ^{[17
]}

Al-Hader, Ahmad ^{[16
]}

Abu Ghazal, Batool ^{[18
]}

Saeed, Anwaar ^{[18
,19
]}

Drolen, Claire ^{[20
]}

Lechner, Melissa G. ^{[20
]}

Drakaki, Alexandra ^{[20
]}

Baena, Javier ^{[21
]}

Nebhan, Caroline A. ^{[22
]}

Haykal, Tarek ^{[23
]}

Morse, Michael A. ^{[23
]}

Cortellini, Alessio ^{[24
,25
]}

Pinato, David J. ^{[24
,26
]}

Dalla Pria, Alessia ^{[24
,25
,27
]}

Hall, Evan ^{[28
]}

Bakalov, Veli ^{[29
]}

Bahary, Nathan ^{[29
]}

Rajkumar, Aarthi ^{[30
]}

Mangla, Ankit ^{[30
]}

Shah, Vishal ^{[31
]}

Singh, Parminder ^{[31
]}

Nana, Frank Aboubakar ^{[32
]}

Lopetegui-Lia, Nerea ^{[33
]}

Dima, Danai ^{[33
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Yale Univ, Sch Med, New Haven, CT USA

[3] Brigham & Womens Hosp, Boston, MA USA

[4] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[5] Univ Illinois, Div Hematol Oncol, Ruth M Rothstein CORE Ctr, Cook Cty Hlth & Hosp Syst,Cook Cty Hosp, Chicago, IL USA

[6] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA

[7] Ohio State Univ, Div Med Oncol, Ctr Comprehens Canc, Columbus, OH USA

[8] Ohio State Univ, Div Hematol, Comprehens Canc Ctr, Columbus, OH USA

[9] Univ N Carolina, Div Hematol, Chapel Hill, NC USA

[10] Univ Texas MD Anderson Canc Ctr Houston, Houston, TX USA

[11] Assiut Univ Hosp, Fac Med, Assiut, Egypt

[12] Cook Cty Hlth, Div Urol, Dept Surg, Chicago, IL USA

[13] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA

[14] Georgetown Washington Hosp Ctr, Medstar, Washington, DC USA

[15] Mem Sloan Kettering Canc Ctr, New York, NY USA

[16] Indiana Univ Sch Med, Indiana Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN USA

[17] Emory Univ, Div Infect Dis, Sch Med, Dept Med, Atlanta, GA USA

[18] Kansas Univ, Canc Ctr, Kansas City, KS USA

[19] Univ Pittsburgh, Hillman Canc Ctr, Pittsburgh, PA USA

[20] Univ Calif Los Angeles, Los Angeles, CA USA

[21] 12 De Octubre Univ Hosp, Madrid, Spain

[22] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA

[23] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC USA

[24] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London, England

[25] Fondazione Policlinico Univ Campus Bio Medico, Med Oncol, Rome, Italy

[26] Univ Piemonte Orientale Avogadro, Dept Translat Med, Novara, Italy

[27] Chelsea & Westminster Hosp, London, England

[28] Univ Washington, Seattle, WA USA

[29] Allegheny Hlth Network, Pittsburgh, PA USA

[30] Univ Hosp, Seidman Canc Ctr, Cleveland, OH USA

[31] Mayo Clin, Phoenix, AZ USA

[32] UCLouvain, Brussels, Belgium

[33] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA

[34] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA

[35] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia

[36] Royal North Shore & Mater Hosp, Sydney, NSW, Australia

[37] Univ Sydney, Melanoma Inst Australia, Fac Med Hlth, Charles Perkins Ctr, Sydney, NSW, Australia

[38] IRCCS Osped Policlinico San Martino, UO Clin Oncol Med, Genoa, Italy

[39] Univ Studi Genova, Dipartimento Med Interna Specialita Med DIMI, Genoa, Italy

[40] IRCCS Osped Policlin San Martino, UO Oncol Med 2, Genoa, Italy

[41] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[42] Univ Calif San Francisco, San Francisco, CA USA

[43] IRCCS Milan, IEO European Inst Oncol, Div Melanoma & Sarcoma Med Treatment, Milan, Italy

[44] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[45] Univ Geneva, Univ Hosp Geneva, Swiss Canc Ctr Leman, Geneva, Switzerland

[46] Univ Hosp Parma, Parma, Italy

[47] Natl Canc Inst, Div Canc Treatment & Diag, Bethesda, MD USA

[48] NCI, NIH, Ctr Canc Res, HIV & AIDS Malignancy Branch, Bethesda, MD USA

[49] AdventHlth Canc Inst, Orlando, FL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 21期

关键词：

LUNG-CANCER; INFECTED PATIENTS; KAPOSIS-SARCOMA; PD-1; BLOCKADE; SINGLE-ARM; PEMBROLIZUMAB; NIVOLUMAB; MULTICENTER; POPULATION; IPILIMUMAB;

D O I：

10.1200/JCO.22.02459

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PURPOSECompared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer.METHODSThis retrospective study included PWH treated with anti-PD-1- or anti-PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC).RESULTSAmong 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti-PD-1/anti-PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts & GE;200 cells/& mu;L, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade & GE;3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was -0.06 months (95% CI, -5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, -4.02 to 8.48; P = .48) for OS.CONCLUSIONAmong PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.

引用

页码：3712 / +

页数：16

共 43 条

[1] Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects?
Abbar, Baptiste
Baron, Marine
Katlama, Christine
Marcelin, Anne-Genevieve
Veyri, Marianne
Autran, Brigitte
Guihot, Amelie
Spano, Jean-Philippe
[J]. AIDS, 2020, 34 (02) : 167 - 175
[2] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Burtness, Barbara
Harrington, Kevin J.
Greil, Richard
Soulieres, Denis
Tahara, Makoto
de Castro, Gilberto, Jr.
Psyrri, Amanda
Baste, Neus
Neupane, Prakash
Bratland, Ase
Fuereder, Thorsten
Hughes, Brett G. M.
Mesia, Ricard
Ngamphaiboon, Nuttapong
Rordorf, Tamara
Ishak, Wan Zamaniah Wan
Hong, Ruey-Long
Mendoza, Rene Gonzalez
Roy, Ananya
Zhang, Yayan
Gumuscu, Burak
Cheng, Jonathan D.
Jin, Fan
Rischin, Danny
[J]. LANCET, 2019, 394 (10212) : 1915 - 1928
[3] Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis
Chaudhary, Omkar
Trotta, Diane
Wang, Kaicheng
Wang, Xun
Chu, Xiuping
Bradley, Chip
Okulicz, Jason
Maves, Ryan C.
Kronmann, Karl
Schofield, Christina M.
Blaylock, Jason M.
Deng, Yanhong
Schalper, Kurt A.
Kaech, Susan M.
Agan, Brian
Ganesan, Anuradha
Emu, Brinda
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
[4] clinicaltrials.gov, TESTING ADDITION EXP
[5] clinicaltrials.gov, NIVOLUMAB IPILIMUMAB
[6] Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review
Cook, Michael R.
Kim, Chul
[J]. JAMA ONCOLOGY, 2019, 5 (07) : 1049 - 1054
[7] PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study
Delyon, Julie
Biard, Lucie
Renaud, Marion
Resche-Rigon, Matthieu
Le Goff, Jerome
Dalle, Stephane
Heidelberger, Valentine
Da Meda, Laetitia
Toullec, Laurie
Carcelain, Guislaine
Mourah, Samia
Caillat-Zucman, Sophie
Allain, Vincent
Battistella, Maxime
Lebbe, Celeste
[J]. LANCET ONCOLOGY, 2022, 23 (04) : 491 - 500
[8] Evans VA, 2018, AIDS, V32, P1491, DOI [10.1097/qad.0000000000001849, 10.1097/QAD.0000000000001849]
[9] fda.gov, ENHANCING DIVERSITY
[10] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Gandhi, L.
Rodriguez-Abreu, D.
Gadgeel, S.
Esteban, E.
Felip, E.
De Angelis, F.
Domine, M.
Clingan, P.
Hochmair, M. J.
Powell, S. F.
Cheng, S. Y. -S.
Bischoff, H. G.
Peled, N.
Grossi, F.
Jennens, R. R.
Reck, M.
Hui, R.
Garon, E. B.
Boyer, M.
Rubio-Viqueira, B.
Novello, S.
Kurata, T.
Gray, J. E.
Vida, J.
Wei, Z.
Yang, J.
Raftopoulos, H.
Pietanza, M. C.
Garassino, M. C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092

← 1 2 3 4 5 →